May 20, 2013
(Stock Blog Hub,
4/4/13)
Novartis (NVS) recently announced that the US Food and Drug Administration (FDA) rendered Breakthrough Therapy designation to its pipeline candidate LDK378.
The Breakthrough...(read more)
(Stock Blog Hub,
4/27/13)
The US Food and Drug Administration (FDA) recently released briefing documents ahead of the review by its Pulmonary-Allergy Drugs Advisory Committee of the New Drug Application (NDA)...(read more)
(Penny Stock DD,
3/22/13)
Novartis AG's (NVS: Quote) TOBI Podhaler has been approved by the FDA for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections.
Cystic...(read more)
Novartis AG (NVS) Company Overview
There is no analysis for NVS yet. But you can go to Wikinvest to help create one! What's in this NVS analysis on Wikinvest...
|
| ||||||
May 20, 2013